Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia
- PMID: 12696001
- DOI: 10.1086/368360
Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia
Abstract
Inner-core lipopolysaccharide (LPS) from Neisseria meningitidis is under investigation as a vaccine for prevention of meningococcal disease caused by N. meningitidis serogroup B (NmB). We investigated the functional activity of murine monoclonal antibody (MAb) B5 that recognizes a highly conserved (galE) LPS epitope. Three patterns of MAb reactivity were observed in N. meningitidis by Western blot, depending on the relative prevalence of sialylated, nonsialylated, and/or truncated LPS glycoforms. Three representative N. meningitidis strains (8047, M986, and 2996) were investigated with MAb B5 in functional assays in vitro and in vivo. MAb B5 completely protected infant rats against bacteremia caused by 8047, partially protected against 2996, and had no protective activity against M986. Thus, an inner-core LPS epitope can be a target for protective immunity, but the affinity of MAb B5 may only be sufficient to mediate protection against NmB strains possessing at least some truncated glycoforms.
Similar articles
-
Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B.Infect Immun. 2001 Jun;69(6):3762-71. doi: 10.1128/IAI.69.6.3762-3771.2001. Infect Immun. 2001. PMID: 11349041 Free PMC article.
-
Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits.Vaccine. 2005 Oct 17;23(43):5045-54. doi: 10.1016/j.vaccine.2005.06.011. Vaccine. 2005. PMID: 16046037
-
Lipopolysaccharide heterogeneity and escape mechanisms of Neisseria meningitidis: possible consequences for vaccine development.Microb Pathog. 1997 Sep;23(3):139-55. doi: 10.1006/mpat.1997.0143. Microb Pathog. 1997. PMID: 9281472
-
[Neisseria meningitidis. The pathophysiological role of lipopolysaccharides in association with meningococcal disease and septic shock].Ugeskr Laeger. 2008 Feb 4;170(6):421-6. Ugeskr Laeger. 2008. PMID: 18252172 Review. Danish.
-
Meningococcal surrogates of protection--serum bactericidal antibody activity.Vaccine. 2005 Mar 18;23(17-18):2222-7. doi: 10.1016/j.vaccine.2005.01.051. Vaccine. 2005. PMID: 15755600 Review.
Cited by
-
Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: chemical strategies to prepare glycoconjugates with good carbohydrate loading.Glycoconj J. 2010 May;27(4):401-17. doi: 10.1007/s10719-010-9287-0. Epub 2010 Mar 26. Glycoconj J. 2010. PMID: 20340043
-
Conjugation of Meningococcal Lipooligosaccharides Through Their Non-Reducing Terminus Results in Improved Induction a Protective Immune Response.Arch Immunol Ther Exp (Warsz). 2019 Aug;67(4):237-248. doi: 10.1007/s00005-019-00542-9. Epub 2019 Apr 27. Arch Immunol Ther Exp (Warsz). 2019. PMID: 31030218 Free PMC article.
-
Hit 'em Where It Hurts: Gram-Negative Bacterial Lipopolysaccharide as a Vaccine Target.Microbiol Mol Biol Rev. 2023 Sep 26;87(3):e0004522. doi: 10.1128/mmbr.00045-22. Epub 2023 Jul 11. Microbiol Mol Biol Rev. 2023. PMID: 37432116 Free PMC article. Review.
-
Review of meningococcal group B vaccines.Clin Infect Dis. 2010 Mar 1;50 Suppl 2(S2):S54-65. doi: 10.1086/648966. Clin Infect Dis. 2010. PMID: 20144017 Free PMC article. Review.
-
Anti-idiotypic antibody as a potential candidate vaccine for Neisseria meningitidis serogroup B.Infect Immun. 2005 Oct;73(10):6399-406. doi: 10.1128/IAI.73.10.6399-6406.2005. Infect Immun. 2005. PMID: 16177311 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical